Kristin M. Stadelman

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

Linda S. Steelman, Patrick M. Navolanic, Melissa L. Sokolosky et al. · Oncogene · 2008 · 171 citations · Full text

Medicine, Cancer Biology, Oncology +14

A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

Timothy S. Pardee, King Lee, John Luddy et al. · Clinical Cancer Research · 2014 · 117 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Yin Yang 1 contains G-quadruplex structures in its promoter and 5′-UTR and its expression is modulated by G4 resolvase 1

Weiwei Huang, Philip J. Smaldino, Qiang Zhang et al. · Nucleic Acids Research · 2011 · 108 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

Melissa L. Sokolosky, Kristin M. Stadelman, William H. Chappell et al. · Oncotarget · 2011 · 82 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells

Melissa L. Sokolosky, William H. Chappell, Kristin M. Stadelman et al. · Cell Cycle · 2014 · 51 citations · Full text

Medicine, Cell Biology, Oncology +17